Subject Index

A

Abdominal fat mass distribution, 103, 124
Aborigines, 23
Acquired hemophilia, 366
ADA annual meeting, 96
Adolescents
  dawn phenomenon, 393
  hypoglycemia, plasma glucagon responses, 643
  nutrition, 192
  self-monitoring of blood glucose, 484
Adrenergic urticaria, 440
Adrenomedullary autoimmunity, 30
Age
  arterial compliance, 787
  at onset
    classification of diabetes, 531
    insulin autoantibodies, 736
    neurobehavioral changes, 86
  oral hypoglycemic agents usage, 558
Alaskan Natives, 693
Albumin
  excretion rate, 509
  glycosylated and elderly, 429
Albuminuria, 371, 840
  See also Microalbuminuria
Alchohol
  abuse and ketoalkalosis, 374
  beer, 659
Alternative sweeteners, 174, 230
  nutrition issues, 194
Amputation, Pima Indians, 8
Angiotensin-converting enzyme inhibitors, 820, 828, 846, 850
Anti-adrenal medullary antibodies, 30
Arterial compliance, 787
Arterial occlusive disease, 345
  lower-extremity progression, 464
Aspartame, 177, 230
Asymptomatic bacteriuria, 708
Atherosclerotic vascular disease, 449
Autonomic nervous system and stress, 83

B

BAYm 1099, 337
β-Blockers, 828
Bimodality, 120
Blindness. *See* Retinopathy
Blood glucose
  carbohydrates, 149
  early-morning rise in children, 574
  enalapril treatment effects, 397
  measurement, 116
  postprandial rise and BAYm 1099, 337
  See also Self-monitoring of blood glucose
Blood pressure, 774
  See also Hypertension

C

Calcium channel blockers, 828, 850
Caloric sweeteners, 174
Carbohydrates
  glycemic index, 149
  insulin requirements, 330
  lunch tolerance, 755
  nutrition issues, 192
Cardiogenic shock, 351
Cardiovascular complications, 103, 449
Catecholamines, 300
Chemstrip reagent strips. *See* Self-monitoring of blood glucose (SMBG)
Children
  cyclosporin A, 447, 510
  dawn phenomenon, 393, 574
  diabetic control and later psychosocial functioning, 387
  early-morning rise in blood glucose, 574
  hypoglycemia, plasma glucagon responses, 643
  neurobehavioral changes, 86
  nutrition, 192
  self-monitoring of blood glucose, 485
  temperament and diabetes, 77
Cholesterol, 129, 546
Classification at time of diagnosis, 531
Clinics and budget cuts, 302
Clofibrate and glucose tolerance, 495
Community care, 519
Complications of diabetes mellitus
  cardiovascular, 103
  common mechanism, 372
  CSII, 370
  dietary protein, 143
  infusion-site and CSII, 50
  interventions to improve care, 275
  neurobehavioral changes, 86
  See also specific diseases in this index
Condylomata acuminata, 295
Conflict of interest, 98, 99
Congenital malformations (CMs), 713
Continuous ambulatory peritoneal dialysis, 373
Continuous subcutaneous insulin infusion (CSII)

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

Subject Index

A

Abdominal fat mass distribution, 103, 124
Aborigines, 23
Acquired hemophilia, 366
ADA annual meeting, 96
Adolescents
  dawn phenomenon, 393
  hypoglycemia, plasma glucagon responses, 643
  nutrition, 192
  self-monitoring of blood glucose, 484
Adrenergic urticaria, 440
Adrenomedullary autoimmunity, 30
Age
  arterial compliance, 787
  at onset
    classification of diabetes, 531
    insulin autoantibodies, 736
    neurobehavioral changes, 86
  oral hypoglycemic agents usage, 558
Alaskan Natives, 693
Albumin
  excretion rate, 509
  glycosylated and elderly, 429
Albuminuria, 371, 840
  See also Microalbuminuria
Alchohol
  abuse and ketoalkalosis, 374
  beer, 659
Alternative sweeteners, 174, 230
  nutrition issues, 194
Amputation, Pima Indians, 8
Angiotensin-converting enzyme inhibitors, 820, 828, 846, 850
Anti-adrenal medullary antibodies, 30
Arterial compliance, 787
Arterial occlusive disease, 345
  lower-extremity progression, 464
Aspartame, 177, 230
Asymptomatic bacteriuria, 708
Atherosclerotic vascular disease, 449
Autonomic nervous system and stress, 83

B

BAYm 1099, 337
β-Blockers, 828
Bimodality, 120
Blindness. *See* Retinopathy
Blood glucose
  carbohydrates, 149
  early-morning rise in children, 574
  enalapril treatment effects, 397
  measurement, 116
  postprandial rise and BAYm 1099, 337
  See also Self-monitoring of blood glucose
Blood pressure, 774
  See also Hypertension

C

Calcium channel blockers, 828, 850
Caloric sweeteners, 174
Carbohydrates
  glycemic index, 149
  insulin requirements, 330
  lunch tolerance, 755
  nutrition issues, 192
Cardiogenic shock, 351
Cardiovascular complications, 103, 449
Catecholamines, 300
Chemstrip reagent strips. *See* Self-monitoring of blood glucose (SMBG)
Children
  cyclosporin A, 447, 510
  dawn phenomenon, 393, 574
  diabetic control and later psychosocial functioning, 387
  early-morning rise in blood glucose, 574
  hypoglycemia, plasma glucagon responses, 643
  neurobehavioral changes, 86
  nutrition, 192
  self-monitoring of blood glucose, 485
  temperament and diabetes, 77
Cholesterol, 129, 546
Classification at time of diagnosis, 531
Clinics and budget cuts, 302
Clofibrate and glucose tolerance, 495
Community care, 519
Complications of diabetes mellitus
  cardiovascular, 103
  common mechanism, 372
  CSII, 370
  dietary protein, 143
  infusion-site and CSII, 50
  interventions to improve care, 275
  neurobehavioral changes, 86
  See also specific diseases in this index
Condylomata acuminata, 295
Conflict of interest, 98, 99
Congenital malformations (CMs), 713
Continuous ambulatory peritoneal dialysis, 373
Continuous subcutaneous insulin infusion (CSII)

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

complications, 370
discontinuation of therapy, 46
hyperglycemia, 372
infusion-site complications, 50
insulin allergy, 97
intense exercise, 311
medical plastics, 370, 371
Coronary heart disease, 351, 449
Cortisol response, 300
CSII. See Continuous subcutaneous insulin-infusion (CSII)
Culture-specific diets, 189
Cyclosporin A
children, 447, 510
new-onset cases of diabetes, 297
C-peptide levels, 318
classification of diabetes, 531
enalapril effects, 397
glipizide, 687, 689, 690

D

Dawn phenomenon, 393, 574
Depression, 605
Diabetic complications. See Complications
Diabetes Control and Complications Trial (DCCT), 567, 725
Diabetic diet. See Diet
Diabetic foot, 819
diagnosis method, 345
hyperbaric oxygen, 111
oxygen content as possible marker, 515
thickened mycotic toenails, 687
Diabetes in pregnancy. See Gestational diabetes mellitus; Pregnancy (preexisting diabetes mellitus)
Diabetic ketoacidosis. See Ketoacidosis
Diabetic ketoalkalosis. See Ketoalkalosis
Diabetic nephropathy. See Nephropathy
Diabetic neuropathy. See Neuropathy
Diabetic retinopathy. See Retinopathy
Diet
alternative sweeteners, 174
beer, 659
behavioral and compliance issues, 197
carbohydrates, 149, 192, 330
change, effects of, 154
culture-specific diets, 189
exercise and low calorie, 208
fat
fat-free diet, 225
modified-fat benefits, 129
recommendations, 195
fiber, 160
fructose, metabolic effect, 546
minority patients, 189
obesity, 183
protein, 143, 146, 195
recommendations for non-insulin-dependent diabetes, 95
sodium, 196
starchy foods, 149
stimulating insulin secretion, 72
vitamins and minerals, 196
weight reduction, 183
See also Nutrition

E

Elevated albumin excretion rate. See Microalbuminuria
Elderly patients
fiber, 166
glycosylated proteins, 429
Enalapril effects, 397
Endocrinology, 676
Erection assistance devices, 445
Exercise, 201
glucose tolerance improvement, 613
high hemoglobin A_1 levels, 422
hyperglycemia after intense, 311
hypoglycemia, 110
insulin absorption, 769
postprandial, 107
running, 1
Eye care, 745

F

Family relations
regimen adherence, 377
stress, 602
Fat
fat-free diet, 225
modified-fat benefits, 129
recommendations, 195
Feet. See Diabetic foot
Fetal macrosomia, 235
Fiber, 160
Foot ulcers. See Diabetic foot
France, pattern of treatment, 586
Free-insulin concentrations and exercise, 110
Fructosamine
glycemic control measurement
glycosylated hemoglobin, comparison, 433
past control, 359
validity, 662
Kawerau population, 239
Fructose
as alternative sweetener, 175
metabolic effect, 546
stimulating insulin secretion, 72

G

Gestational diabetes mellitus
age, 408
evaluating outcomes, 281, 282
family history of diabetes, 408
Mexican population, 235
obesity, 408
perinatal morbidity, 761
preexisting glucose intolerance, 402
prevention, 263
treatment, 813
Glipizide, 687, 689, 690, 751
Glomerulopathy, 846
Glucagon
alternative sweeteners, 230
-stimulated C-peptide, 318
Glucometer II, 116
Glucose
alternative sweeteners, 230
concentrations, biphasic patterns, 99
intolerance, 253
preexisting and gestational diabetes, 402
response to meals, 72, 323, 337
screening test, 235
tolerance
breakfast absorption, 755
clofibrate and improvement, 495
exercise effect, 613
high hemoglobin A_1 levels, 422
α-Glucosidase inhibitor, 337
Glucosylation, 422
Glyburide, 751
Glycemic control
assessment methods, 359
blood dried on filter paper, 222, 223
fructosamine, 359, 433, 662
children
dawn phenomenon, 574
temperament, 77
combination of two sulfonylureas, 751
family relations, 602
fructose, metabolic effect on, 546
painful polyneuropathy, 38
predictors, 798
pregnancy, 713
social environment and regimen adherence, 377
surgery, 55
type A behavior pattern, 361
zincuria, 780
Glycemic index, 149
beer, 659
carbohydrates, 149
criticism of, 323
Glycosylated
albumin, 429
hemoglobin, 429
blood dried on filter-paper measurement, 222, 223
correlation with neurological abnormalities, 473
elderly, 429
fructosamine, comparison, 433
high levels, 422
sample collection paper measurement, 686
thermal sensitivities, 481
hemoglobin A_{1c}, children and temperament, 77
proteins, 429, 433
fructosamine, 433, 662

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

H

Heart, insulin effect on, 500
Height and neuropathy, 444
Hematocrit and blood glucose measurement, 116
Hemoglobin A_1
  high levels, 422
  measurement of, 512
    and mortality, 538
  past glycemic control measurement, 359
  self-monitoring of blood glucose, 484
Hemolytic anemia, effects of pregnancy, 416
Hormones and exercise, 3
Human
  NPH, 562
  proinsulin, 656
  semisynthetic insulin, 59, 61
Hyperbaric oxygen and diabetic foot, 111, 819
Hyperglycemia
  complications development, 372
  exercise, 311
  fasting
    children, 574
    human proinsulin, 656
Hyperinsulinemia
  Aborigines, 23
  SMS 201-995 ineffectiveness, 664
Hyperlipidemia, 129, 165
Hypertension, 820
  antihypertensive therapy
    effect on glomerulopathy, 846
    effect on nephropathy, 850
  etiology, 821
  hypoglycemic stress, 300
  non-insulin-dependent diabetes, 17
    enalapril effects, 397
  pregnancy, effects of, 416
  prevalence, 821
  retinopathy, relationship to, 246
  treatment, 828
Hypertriglyceridemia. *See* Triglycerides
Hypoglycemia
  agents, 63
  exercise, 107
  neurobehavioral changes, 86
  nocturnal
    monitors, 630
    relationship to daytime glycemia, 636
  plasma glucagon responses, 643
  postprandial, 439
Hypouricemia, 796

I

IDDM. *See* Insulin-dependent diabetes mellitus
Impaired glucose tolerance
  Aborigines, 23
  case definition, 121
  genetic markers, 511
  gestational diabetes mellitus, 402
Impotence, 445
Incipient diabetic nephropathy, 371
Insulin
  absorption
    accidental intramuscular injection, 41
    stress effect, 650
    kinetics, 739
    through eyes, 750
  allergy, 59, 365, 366
    CSII, 97
  alternative sweeteners, response to, 320, 233
  arterial compliance, 787
  autoantibodies, 736
  concentrations, biphasic patterns, 99
  enalapril treatment effects, 397
  exercise effect, 769
  flocculation, 563
  growth factor, 500
  injections
    accidental intramuscular injection, 41
    jet injections, 298, 600, 739
    multiple and exercise, 107
    single use syringes, 817
    techniques, 733
  intensified therapy
    nutrition, 197
    weight gain, 567
  lipoatrophy, 59
  meals, response to, 72, 323
  metabolism, glipizide effect on, 687, 689, 690
  potency, 563, 604
  precipitation, 563
  receptors
    clofibrate, 495
    fructose, metabolic effect of, 546
  requirements
    fat-free diet, 225
    mixed-carbohydrate diet, 330
    surgery, 52
  resistance, 119
    decrease with exercise, 613
    skin, ovarian and cardiac abnormalities, 500
  salivary, 489
  secretion, 119
    diet as factor, 72
    glipizide effects on, 687, 689, 690
  sensitivity, 63, 755
  shortage, 97
  single use syringes, 817
  stability, 563
  surgery, 52
  unused, collection of, 97
Insulin-dependent diabetes mellitus
  adolescents
    hypoglycemia, plasma glucagon responses, 643
    nutrition, 192
    self-monitoring of blood glucose, 484
  anti-adrenal medullary antibodies, 30
  children, 77
    dawn phenomenon, 574
    diabetic control and later psychosocial functioning, 387
    early-morning rise in blood glucose, 574
    hypoglycemia, plasma glucagon responses, 643
    nutrition, 192
    self-monitoring of blood glucose, 484
    temperament, 77
  classification, 531
  condylomata acuminata, 295
  congenital malformations, 713
  CSII therapy, 46
    complications, 370
  cyclosporin A, 297
  diet
    alcohol, 659
    carbohydrates, 149, 330
    fat-free, 225
    fat-modified, 129
    fat recommendations, 192
    fiber, 160
    protein, 143
  exercise, 1, 107, 201
    hyperglycemia, 311
  glycemic index, 150
  hypoglycemia
    nocturnal, 630, 636
    plasma glucagon responses, 643
  immunogenetic markers, 510, 511
  insulin
    accidental intramuscular injection, 41
    allergy, 59
    autoantibodies, 736
    intensive therapy and weight gain, 567
    salivary, 489
  islet cell antibody, 367, 439
  jet injections, 298, 600, 739
  lipid concentrations, 129
  lipoatrophy, 59
  motor-vehicle accidents, 701
  neurobehavioral complications, 86
  neurological abnormalities, 473
  nutrition guidelines, 192
  outpatient care, 294
  pancreas transplant, 669
  pan-pancreatic involvement, 100
  prediction, 439, 510, 511, 798
  pregnancy, effects on renal and ocular disease, 416
  primary prevention, 258
  psychosocial variables, 602
  quality-of-life measure, 725
  retinopathy, 441
  salivary insulin, 489
  self-monitoring of blood glucose
    accuracy and adherence to regimen, 579
    effectiveness, 484
  type A behavior pattern, 361
  young adult nutrition, 192
  zincuria, 780
Insulin-specific IgG, 59
Insulin-specific IgE, 59

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

Intravenous tolbutamide test, 444
Islet cell antibody
  adrenomedullary autoimmunity, 30
  assay, 367
  predictive marker for insulin-dependent diabetes, 439

J
Jet injections, 298, 600, 739

K
Kawerau population, 239
Ketoacidosis, CSII therapy, 49
Ketoalkalosis, 368
  alcohol abuse, 374

L
Lipids
  fat-modified diet, 129
  metabolism and fructose, 546
  nutrition issues, 195
Lipoproteins
  fat-modified diet, 129
  intermediate density, 794
  lower-extremity arterial occlusive disease, 464
Lower-extremity arterial occlusive disease, 464

M
Marathon running. *See* Exercise
Meal plans
  breakfast absorption, 755
  nutrition issues, 193
Medical plastics and CSII, 371
Medical-care satisfaction and regimen adherence, 377
Memory meters. *See* Self-monitoring of blood glucose
Metabolic control
  BAYm 1099, 337
  fructose, 546
  insulin injection technique, 41
  neurobehavioral changes, 86
  neurological abnormalities, correlation with, 473
  perinatal morbidity prevention, 761
Metabolism
  exercise, 1
  surgery, 57
Mexican population, 235, 254
Microalbuminuria, 509, 527, 840
Minority groups and diet therapy, 189
Mortality
  amputations (Pima Indians), 8
  glucose intolerance as risk factor, 253
  perinatal prevention, 761
  premature (Nauruans), 305
  psychosocial variables, 538, 544
Motor-vehicle accidents, 701, 749
Myocardial infarction
  acute, 351
  high hemoglobin A_1 levels, 426
  risk factors, 449

N
National Task Force on Diabetes and Vision Impairment, 753
Nauruans, 254, 305
Nephropathy, 820, 833
  health-care costs, 833
  microalbuminuria, 527, 840
  pancreatic transplantation, 669
  pregnancy effects, 416
  screening methods, 371
Neurological abnormalities, 473
Neuropathy, 592
  autonomic
    blood pressure, 774
    pregnancy, 369
  height, 444
  warm and cool sensitivities, 481
  See also Painful neuropathy; Painful polyneuropathy
Neurophysiology measurements, 34
NIDDM. *See* Non-insulin-dependent diabetes mellitus
Nigerians, 412
Noncaloric sweetener, 174, 230
Noncommunicable diseases, 253
Non-insulin-dependent diabetes mellitus
  abdominal fat mass distribution, 103
  Aborigines, 23
  amputation (Pima Indians), 8
  arterial compliance, 787
  asymptomatic bacteriuria, 708
  atherosclerotic vascular disease, 449
  BAYm 1099, 337
  case-control studies, 119
  cholesterol, 130
  classification, 531
  diet
    carbohydrates, 149
    fiber, 160
    minority patients, 189
    modified-fat, 129
    obesity, 183
    protein, 144
    recommendations, 95
    stimulating insulin secretion, 72
  enalapril effects, 397
  exercise, 201, 613
  fructose, metabolic effect, 546
  genetic markers, 511
  glipizide effects, 687
  glucose tolerance
    clofibrate, 495
    exercise, 613
  glycemic index, 150
  glycosylated hemoglobin measurement, 512
  human proinsulin and fasting hyperglycemia, 656
  hypertension, 17
    enalapril effects, 397
  hypouricemia, 796
  intravenous tolbutamide test, 444
  lipid concentrations, 129
  lower-extremity arterial occlusive disease, 464
  Mexican population, 235, 254
  Nauruans, 305
  neurological abnormalities, 473
  nopal intake, 63
  obesity
    dietary considerations, 183
    fat mass distribution, 103
    genetic markers, 511
  oral hypoglycemic agents, 558
  patient education, 67
  Pima Indians, 8, 254
  postprandial blood glucose, 337, 342
  primary prevention, 258
  prospective studies, 122
  psychosocial variables, 538
  record books, 299
  regimen adherence, 377
  stress, 83
  treatment
    nopal intake, 63
    patterns in France, 586
  uric acid, 796
  weight reduction, 183
Nopal intake, 63
NovoPen, 373
NPH human insulin, 563
Nutrition, 127
  adolescents, 192
  children, 192
  deficiencies and painful neuropathy, 748
  guidelines for insulin-dependent diabetes, 192
  young adults, 192
  See also Diet

O
Obesity
  abdominal fat mass distribution, 103
  dietary considerations, 183
  fiber, 166
  genetic markers, 511
  prospective studies, 124
  weight reduction, 183
Onychomycosis, 687
Ophthalmic exams, 745
Opiate addiction, 443
Oral glucose tolerance test
  gestational diabetes and preexisting glucose intolernace, 402
  pregnant Nigerian women, 412
  vomiting, 818

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

Oral hypoglycemic agents, 558
Outpatient care, 294
Ovary, insulin effect on, 500

P

Painful neuropathy, 748
Painful polyneuropathy, 34
Pancreas transplant, 669, 681
Pan-pancreatic involvement, 100
Patient education, 214-218
  minority patients and nutrition, 189
  small group, 67
Peripheral vascular disease, 345
Peroxidase protein A, 367
Physical activity. *See* Exercise
Pima Indians
  amputation, 8
  insulin resistance, 119
  prevalence and incidence of diabetes, 254
Plasma fibronectin, 527
Plasma glucose
  bimodality, 120
  exercise, effect of, 107
  fasting and elderly, 429
  postprandial, 512
  retinopathy, relationship to, 246
Postprandial
  C-peptide, 318
  exercise, 107
  glucose and insulin peaks, 99
  hypoglycemia, 439, 769
  plasma glucose, 512
Postural hypotension during pregnancy, 369
Pregnancy (preexisting diabetes mellitus)
  autonomic neuropathy, 369
  congenital malformations, 713
  CSII therapy, 49
  evaluating outcomes, 281
  fiber, 166
  postural hypotension, 369
  prevention, 263
  renal and ocular disease, 416
  third-trimester vomiting, 818
  See also Gestational diabetes mellitus
Prevalence
  Alaskan Natives, 693
  asymptomatic bacteriuria, 708
  atherosclerotic vascular disease, 449
  country development as factor, 296, 297
  hypertension, 17, 821
  Kawerau population, 239
  Mexican population, 235
  Nauruans, 305
  Pima Indians, 8, 254
Prevention, 258, 263, 275
Primary care, 269, 275
Professional-patient interaction, 743
Protein
  dietary recommendations, 143
  glycemic control measurement, 433
  glycosylated and elderly, 420
  nutrition issues, 195
  stimulating insulin secretion, 72
Psychiatric disorders, 605
Psychosocial
  functioning, 387
  variables
    predictors, 602, 798
    self esteem, 551
    survival, 538

Q

Quality-of-life measure, 725

R

Reagent strips. *See* Self-monitoring of blood glucose
Reflectance meters. *See* Self-monitoring of blood glucose
Regimen adherence
  self-monitoring of blood glucose, 579
  social environment, 377
Retinopathy
  blood pressure, relationship to, 246
  plasma glucose, relationship to, 246
  psychological effect, 551
  SMS 201-995 effect, 441
Risk factors
  amputations, 8
  atherosclerotic vascular disease, 449, 794
  hypertension, 17
  insulin secretion and resistance, 119
  mortality, 253
  obesity, 124

S

Saccharin, 178, 230
Salivary insulin, 489
School bus driver, 749
Screening tests
  fructosamine measurement, 239
  glucose screening test, 235
Self esteem, 551
Self-monitoring of blood glucose (SMBG)
  accuracy of data, 579, 603, 791
  computer-generated formats, 514
  effectiveness of, 485
  monitors
    auditory feedback, 753
    Chemstrip reagent strip, 288, 619
    comparisons, 219, 220, 221, 747, 748
    confidence levels, 808
    evaluation of devices, 288, 619, 801
    filter-paper accuracy, 517
    memory meters, 579, 719
    reference standards, 219
    study clarification, 446
    visually impaired users, 753
  regimen, adherence to, 579
Skin, insulin effect on, 500
Sleep Sentry, evaluation, 630
Smoking
  atherosclerosis, 422, 449
  lower-extremity arterial occlusive disease, 464
SMS 201-995, 441, 664
Social environment and regimen adherence, 377
Social impact of disease, 538, 542
Social support and regimen adherence, 377
Sodium, nutrition issues, 196
Somogyi phenomenon, 574
Stress
  autonomic nervous system, 83
  family relations, 602
  insulin absorption, 650
  regimen adherence, 377
Sulfonylureas, 689, 690, 751
Surgery and insulin treatment, 52
Sympathetic nervous system and stress, 83

T

Thermal sensitivity, 481
Topical hyperbaric oxygen. *See* Hyperbaric oxygen
Triglycerides
  Aborigines, 23
  clofibrate, 495
  control of, 794
  elevated levels, 130
  fructose, metabolic effect on, 546
Type I diabetes. *See* Insulin-dependent diabetes mellitus
Type II diabetes. *See* Non-insulin-dependent diabetes mellitus
Type A behavior pattern and glycemic control, 361

U

Uric acid, 796
Urine collection, 371, 509

V

Vasculopathy, 713
Vitamins and minerals, 196
Vomiting, 818

W

Weight
  classification of diabetes, 531
  gain and intensive insulin therapy, 567
  loss and painful neuropathy, 748
  reduction, 183

Y

Young adults and nutrition, 192

Z

Zincuria, 780

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

Author Index

A

Abe, N., 515
Abourizk, N.N., 215
Abraham, G., 305
Adelusi, B.O., 412
Adkins, R.H., 111, 819
Adri, M.N.S., 30
Ahuja, M.M.S., 95
Aizawa, T., 796
Albert, S.G., 551
Alberti, K G.M.M., 337
Alford, J.B., 719
Altamirano, P., 63
Amadin, R.A., 412
American Academy of Neurology, 592
American Diabetes Association, 592, 600, 745
American Foundation for the Blind, 753
Anderson, B., 801
Anderson, R.M., 214, 519
Anderson, S., 846
Andreani, D., 439, 473
Anfossi, G., 107
Anichini, R., 509
Ansaldi, S.G., 59
Aoyama, K., 444
Ariza, C.R., 63
Audi, L., 298
Ayyar, D.R., 481

B

Baba, S., 495, 794
Bailey, G.J., 46
Baker, J., 239
Ballard, J.L., 713
Banerjee, A.K., 366
Barbosa, J., 510
Barlascini, C.O., 755
Barnes, K., 393
Barolo, P., 59
Barreau, P.B., 116, 748
Bartolomei, G., 527
Baum, C., 558
Beach, K.W., 464
Becker, D.J., 643, 701
Beck-Nielsen, H., 531
Bedford, G.R., 464
Bell, D.S.H., 295, 511
Belmonte, M.M., 387, 484
Bender, A.P., 17
Benson, E.A., 563
Benson, J.W., Jr., 563
Ben Yosef, N., 422
Ben Yosef, S., 422
Bergelin, R.O., 464
Berger, M., 659, 733
Berk, M.A., 713
Bernbaum, M., 551
Bernstein, R.K., 687
Berntzen, P.A., 739
Bichler, A., 761
Blackard, W.G., 755
Blatto, A., 59
Bloomgarden, Z.T., 218
Boden, G., 664
Bonora, E., 52, 690
Bornet, F., 546
Bosquet, F., 371
Boyko, E.J., 693, 708
Brackenridge, B.P., 215
Braunsteiner, H., 761
Braveman, P., 281
Breier, C., 761
Brenner, B.M., 820, 846
Bringer, J., 850
Brink, S.J., 192
Bros, M., 546
Broussolle, C., 687
Brown, F.M., 30
Brown, W.V., 218
Browner, W., 281
Bruni, B., 59
Buoninconti, R., 300
Bureau, G., 371
Butler, N., 297
Buttery, J.E., 116, 748
Buzzetti, R., 299

C

Cahill, C., 367
Calles-Escandon, J., 94, 212
Camus, F., 506
Capelli, C.C., 801
Capitol-Ade Executive Committee, 216
Capps, R.A., 818
Carlini, M., 59
Carlson, A., 269
Carroll, P.B., 225
Carta, Q., 107
Carter, W.R., 579, 630
Caselli, P., 527
Cassorla, F., 393
Castillo, M.J., 687
Catalano, P.M., 292

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

Cathelineau, G., 586
Cefalu, W.T., 662
Ceriello, A., 372, 443
Chang, M.S., 750
Chantelau, E., 371, 659, 733
Chase, H.P., 297
Chiou, G.C.Y., 750
Chuang, C.Y., 750
Chung, H., 441
Cimicchi, M.C., 52
Cimino, A., 97
Clarke, B.F., 34, 433
Clarke, W.L., 288, 370, 579, 630
Clements, R.S., Jr., 295, 511
Clore, J.N., 755
Clouse, R.E., 605
Cocozza, S., 511
Cohen, M., 747
Cohen, R.M., 506
Colagiuri, S., 365
Colette, J., 216
Colman, P.G., 367
Contaldo, F., 511
Contini, S., 52
Contreras-Soto, J.J., 235
Copeland, K.C., 94
Costa, F.M., 780
Coulston, A.M., 323
Coutarel, P., 371
Covarrubias, B.M., 817
Cox, D.J., 288, 517, 579, 630
Crapo, P.A., 174
Creten, W., 103
Creutzfeldt, W., 439
Cruickshanks, K.J., 701
Cryer, P.E., 630
Cutter, G.R., 295

D

Dandona, P., 748
Dannehl, K., 619
Dauchy, F., 546
Davis, C.E., 574
Davis, W.K., 519, 538
The DCCT Research Group, 567, 725
Deeb, L.C., 252, 275
De Facis, R., 107
De Giorgio, L.A., 527
De Leeuw, I., 103
Dellit, L., 365
Devlin, J.T., 94, 212, 363
Dib, S., 736
Dignan, P.St.J., 713
Di Mario, U., 473
Dominiczak, M.H., 359
D'Onofrio, F., 300, 372
Dorman, J.S., 701
Drash, A.L., 643, 701
Draznin, B., 445
Drexel, H., 761
Duarte, P.M., 296
Duckro, P.N., 551
Dudley, J.D., 791
Dufresne, J., 484
Duncan, B.B., 574
Dunn, F.L., 225
Dyson, A.J., 366

E

Ehrlich, R.M., 77, 98
Ehsani, A.A., 613
Eicke, F.J., 603
Eisenbarth, G.S., 367, 736
Elliott, T.W., 397
Ellis, B., 791
Ellis, G.J., III, 574
El-Zubier, A.G., 297
Emanuelli, G., 107
Eross, J., 686
Everhart, J.E., 8
Ewing, D.J., 34

F

Faber, O., 531
Fachnie, J.D., 818
Famuyiwa, O.O., 412
Fatani, H.H., 297
Feinglos, M.N., 83
Fernqvist, E., 650
Figueiredo, A., 440
Finch, C.F., 305
Fiore, V., 299
Flores, G., 235
Fong, G., 235
Fonseca, V., 748
Fontvieille, A.M., 546
Forsbach, G., 235
Foz, M., 298
Frank, H.J.L., 774
Frati-Munari, A.C., 63
Fredlund, P.N., 563
Freeman, G., 275
Frid, A., 41
Fulop, M., 374
Fyhrquist, F., 689

G

Gadia, M.T., 481
Gannon, M.C., 72
Geffner, M.E., 500
Gershberg, H., 294
Giampietro, O., 509
Gifford-Jorgensen, R.A., 446
Gilligan, J.E., 818
Ginunas, V.J., 111, 819
Gironi, A., 527
Giugliano, D., 372, 443
Glasgow, R.E., 377
Gleason, R., 330
Glugla, M., 445
Gnudi, A., 52
Goday, A., 439
Gohdes, D.M., 8, 189, 693
Golde, D.W., 500
Golden, M.P., 514
Goldman, H., 484
Goldstein, D.E., 222
Goldstein, I.B., 774
Gomis, R., 439
Goncalo, M., 440
Gonder-Frederick, L.A., 288, 517, 579, 630
Gordillo, B.E., 63
Gorman, D.F., 818
Goto, S., 444
Grabauskas, V.J., 253
Grassi, G., 59
Gries, F.A., 619
Griffith, L.S., 605
Grigoresco, C., 546
Grimaldi, A., 371
Groop, L.C., 689, 751
Groop, P.-H., 689
Grove, N.P., 298
Guinn, T.S., 46
Gunnarsson, R., 41
Güntner, P., 41

H

Hagberg, J.M., 613
Halfon, P., 546
Halkin, H., 422
Hamman, R.F., 708
Hammon, R., 297
Handelsman, D.J., 719
Hansen, B.C., 183
Hanson, C.L., 602
Harding, P.E., 818
Harris, M.I., 402
Harrison, K.M., 366
Hartner, J.A., 8
Hayashi, M., 444
Hayward, A., 297
Heere, L.P., 1
Heine, R.J., 739
Heise, C.C., 780
Heiss, G., 574
Heller, A., 387
Herrman, J., 288
Herskowitz, R.D., 736
Hess, G.E., 519, 538
Hirata, Y., 495
Hirsch, S.R., 656
Hiss, R.G., 519, 538
Hoffman, R.P., 643
Hollenbeck, C.B., 323
Holloszy, J.O., 613
Home, P., 604
Hopper, J.L., 23
Horiya, T., 444
Horton, E.S., 94, 201
Horwitz, D.L., 230
Hoskins, P.L., 719
Hoskinson, L.L., 219
Hother-Nielsen, O., 531
Houtzagers, C.M.G.J., 739

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

Howie, A.F., 433
Hunt, C., 216

I

Insua, A., 850
Irjala, K.M.A., 318
Isernia, C., 511
Ishihara, M., 796
Ito, Y., 444
Itoh, T., 100
Iwai, M., 794
Iwatani, I., 794

J

Jagger, H.G., 17
Jaspan, J.B., 99
Jenkins, A.L., 149
Jenkins, D.J.A., 149, 160
Jensen, I.W., 368
Jensen, R.L., 808
Jensen, S., 368
Jimenez, M., 686
Johnson, C.R., 662
Jones, D.B., 416
Jones, R.E., 220
Jones-Garrison, S., 517
Joseph-Tipton, N., 801
Jovanovic-Peterson, L., 791
Julian, D.M., 579

K

Kabadi, U.M., 429
Kahn, C.R., 330
Kallio, V., 449
Kamalesh, M., 30
Kasama, T., 794
Kashiwagi, A., 515
Kato, M., 481
Kazumi, T., 794
Keane, E.M., 708
Keller, R.J., 736
Kelly, T.M., 808
Kennedy, D.L., 558
Kennedy, L., 512
Kenny, J., 216
Kerensky, K., 643
Khoury, J., 713
Kibarian, M., 393
Kida, Y., 515
Kilo, C., 791
King, D.S., 613
King, H.O., 305
King, J.C., 780
Kinzel, L., 330
Kissebah, A., 129
Kitagawa, T., 447
Kitzmiller, J.L., 780
Klingensmith, G., 297
Knowler, W.C., 8
Kobayashi, M., 495
Kobayashi, T., 100
Kobe, P., 230
Koch, D.D., 801
Kodama, M., 515
Koh, C.-S., 441
Koivisto, V.A., 769
Kopecky, R.T., 416
Kosaka, K., 100
Koschinsky, T., 619
Koskinen, P.J., 318
Koumoulidou, J., 733
Kreisberg, R.A., 676
Kreutzmann, D., 686

L

Laakso, M., 449
Lane, J.D., 361, 798
Langer, O., 263
Lanier, A.P., 693
LaPorte, R.E., 701
Larkins, R.G., 23
Lawrence, C., 374
Lebovitz, H.E., 598, 656
Lee, H.K., 441
Lee, J.H., 441
Lefebvre, P.J., 439, 687
Leiter, L.A., 311
Lerman, I.G., 636
Leslie, C.A., 111, 819
Linde, B., 41, 650
Lisch, H.-J., 761
Little, R.R., 222
Litton, J.C., 361, 798
Llewelyn, J.G., 366, 748
Lo, C.S., 787
Lowitt, S., 298
Lucas, A., 298
Lucchina, P.G., 107
Ludvigsson, J., 447
Luft, R., 269
Lusky, A., 422
Lustman, P.J., 605

M

Malone, J.I., 298
Marin, G., 393
Marks, V., 439
Marliss, E.B., 311
Marrero, D.G., 514
Martin, D.C., 464
Massucco, P., 107
Mathews, J.H., 736
Matsuba, K., 794
Matsushita, M., 794
Mazze, R.S., 263
Mazzuca, S.A., 514
McCance, D.R., 512
McCarthy, J.A., 817
McGrath, Z., 818
McLane, M., 230
McNaught, J., 359
McPherson, M., 369
Meccia, A., 473
Mecklenburg, R.S., 46, 563
Meinders, A.E., 1
Melander, A., 689
Mengel, M.B., 602
Meridan T., 96
Metcalf, P., 239
Metz, R., 563
Metzger, B.E., 813
Meytes, D., 422
Miccoli, R., 509
Mimouni, F., 713
Mimran, A., 850
Min, H.K., 441
Miodovnik, M., 713
Mira, S.A., 297
Mitchell, T.H., 311
Miura, K., 444
Modan, M., 422
Moll, M., 630
Moll, M.E., 517
Mollica, M.A., 473
Monnier, L., 850
Monticelli, A., 511
Moore, M.P., 397
Moore, W.V., 446
Morano, S., 473
Moreno, O., 235
Morocutti, C., 473
Morris, M.A., 361, 798
Muggeo, M., 690
Mularoni, E., 107
Munoz, A., 439
Murase, T., 100
Murphy, N.J., 693
Myers, K.A., 787

N

Nagasawa, Y., 796
Nakanishi, K., 100
Naliboff, B.D., 774
Nambu, S., 495
Narins, B.E., 833
Narins, R.G., 833
Navalesi, R., 509
Nelson, R.G., 8
Nestler, J.E., 755
Nicholls, M.G., 397
Nishio, Y., 515
Nubiola, A., 439
Nuttall, F.Q., 72, 99

O

O'Brien, D., 297
O'Connor, P.J., 215
O'Dea, K., 23
Occhigrossi, F., 300
Omori, Y., 495
Orchard, T.J., 701
Oswald, G.A., 351

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

P

Paiva, I., 440
Paolisso, G., 300
Papatheodorau, N., 216
Papoz, L., 586
Parker, T.B., 662
Parsons, D.W., 818
Pasic, J., 489
Pasmantier, R., 656
Paterson, K.R., 359
Patsch, J.R., 761
Pelizzari, R., 97
Pellegrino, A., 511
Penno, G., 509
Penttilä, I, 449
Peterson, C.M., 791
Pettijohn, F.P., 275
Pettitt, D.J., 8
Pezzarossa, A., 52
Phillips, D.M., 603
Pickup, J.C., 489
Piper, C.M., 330
Piper, J.M., 558
Plaza, C., 439
Pless, I.B., 387
Poiares-Baptista, A., 440
Polychronakos, C., 484
Pontesilli, O., 297
Potter, D.M., 749
Pozzessere, G., 473
Pozzilli, P., 300
Puukka, P., 449
Pyöralä, K., 449

Q

Quatraro, A., 372, 443

R

Raab, R.S., 97
Rabinowe, S.L., 30
Rabizadeh, A., 367, 736
Raz, I., 67
Reaven, G.M., 323
Reller, L.B., 708
Replogle, W.H., 603
Reschke, J., 288
Rhodes, R.K., 801
Ribas, L., 298
Ribstein, J., 850
Ricker, A.T., 736
Rillaerts, E., 103
Ritchie, C.M., 512
Rizkalla, S.W., 546
Rizzo, P.A., 473
Robbins, D.C., 94, 99, 212, 363, 743
Roberts, A.P., 818
Robinson, M.K., 808
Rocca, L., 97
Rogers, M.A., 613
Romera, G.S., 370
Rönnemaa, T., 449, 769
Rose, S.R., 393
Rosenqvist, U., 269
Ross, S.L., 361, 798
Rossini, E., 52
Rotondi, A., 97
Rovet, J.F., 77
Rozeman, P., 422
Ryan, C.M., 86
Ryan, I.G., 664

S

Sacerdote, A.S., 302, 440
Sailer, S., 761
Sakamoto, N., 495
Salinas, I., 298
Salo, S., 751
Saloranta, C., 689
Samad, A.H.B., 337
Sanders, S.D., 603
Sanmarti, A., 298
Sapico, F.L., 111, 819
Sartorius, E.A., 370
Saudek, C.D., 223, 687
Savory, J., 517
Scalfi, L., 511
Schectman, G., 129
Scheen, A.J., 687
Schiffrin, A., 98, 311, 484
Schmidt, M.I., 574
Schnell, H., 246
Schönbach, A.-M., 659
Schooneveldt, M.G., 305
Schraer, C.D., 693
Scott, A.R., 369
Scragg, R., 239
Seghieri, G., 527
Sehayek, E., 422
Selby, J., 281
Sepe, S., 281
Sgambato, S., 300
Shah, S.C., 298
Shapiro, D., 774
Shigeta, Y., 495, 515
Shinoda, T., 796
Shirah, J.K., 275
Shirota, T., 796
Showstack, J., 281
Shults, M.C., 801
Shuman, C.R., 664
Siddiqi, T.A., 713
Silink, M., 686
Simonson, D.C., 821
Simpson, J.M., 787
Simpson, R.W., 787
Singer-Granick, C., 643
Sink, P.F., Jr., 817
Slama, G., 546
Smart, L.M., 433
Smith, A.F., 433
Smith, L.A., 359
Snyder, A., 288
Soeldner, J.S., 736
Songer, T.J., 701
Sørensen, N.S., 531
Sosenko, J.M., 481
Soskolne, V., 67
Soto, R.A., 481
Sprafka, J.M., 17
Spraul, M., 659, 733
Stabler, B., 361, 798
Starrett, K., 216
Stein, P., 67
Steiner, J.F., 221
Stenman, S., 689
Stern, M.P., 119
Stork, W., 345
Strandness, D.E., Jr., 464
Sugimoto, T., 100
Suh, K.I., 441
Suissa, S., 484
Sunderji, S., 416
Surwit, R.S., 83, 361, 798
Sutherland, D.E.R., 681

T

Taddei, F., 52
Takeda, N., 444
Tattersall, R.B., 369
Tautkus, M., 367
Taylor, R., 337
Tchobroutsky, G., 546
Teuscher, A., 246
Teutsch, S., 281
Thervet, F., 371
Thoma, K., 305
Thomas, P.K., 748
Toobert, D.J., 377
Torella, R., 300
Tosoni, C., 97
Totterman, K.-J., 689
Traianedes, K., 23
Trovati, M., 107
Tsang, R.C., 713
Tuck, M., 828
Turtle, J.R., 719
Ty Willing, T.S., 337

U

Uggeri, E., 52
University of Michigan Pancreas Transplant Evaluation Committee, 669
Updike, S.J., 801

V

Valentini, U., 97
Valle, E., 473
Vandenberghe, N., 464

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80

Van Cauter, E., 99
Van Crombrugge, P., 373
Van der Stap, H., 739
Van der Veen, E.A., 739
Van Gaal, L., 103
Vardi, P., 736
Varricchio, M., 300
Vasquez, B., 99
Vaughan, N., 219
Vauzelle, F., 586
Vendrell, J., 439
Vexiau, P., 586
Viberti, G., 840
Viikari, J.S.A., 318
Vinik, A.I., 127, 160
Vitali, S., 107
Vlachokosta, F.V., 330
Vogelberg, K.H., 345
Von Heimburg, D., 801

W

Wahlqvist, M.L., 787
Walker, S.W., 433
Waller, J.V., 444
Weinstock, R.S., 416
Whitehouse, F.W., 818
Whitley, R.J., 295
Willekens, F.L.A., 1
Wilson, P.W.F., 246
Wolever, T.M.S., 149
Wolfsdorf, J.I., 636, 736
Wylie-Rosett, J., 143

Y

Yamada, T., 796
Yamamoto, C., 613
Yasuda, K., 444
Yoshino, G., 794
Young, R.J., 34, 433
Yudkin, J.S., 351
Yue, D.K., 719

Z

Zaccardi, M., 464
Ziegler, A.G., 736
Zimmet, P.Z., 258, 305
Zvagulis, I., 387
Zwemer, F.L., 8

DIABETES CARE: VOLUME 11 (1988) PAGE NUMBERS BY ISSUE

January, 1–101
February, 103–223
March, 225–303
April, 305–375
May, 377–447
June, 449–518
July/August, 519–604
September, 605–692
October, 693–754
November/December, 755–853
Supplement 1, 1–80